K. Bremer

673 total citations
55 papers, 340 citations indexed

About

K. Bremer is a scholar working on Genetics, Oncology and Molecular Biology. According to data from OpenAlex, K. Bremer has authored 55 papers receiving a total of 340 indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Genetics, 15 papers in Oncology and 11 papers in Molecular Biology. Recurrent topics in K. Bremer's work include Chronic Lymphocytic Leukemia Research (14 papers), Lymphoma Diagnosis and Treatment (8 papers) and Nausea and vomiting management (4 papers). K. Bremer is often cited by papers focused on Chronic Lymphocytic Leukemia Research (14 papers), Lymphoma Diagnosis and Treatment (8 papers) and Nausea and vomiting management (4 papers). K. Bremer collaborates with scholars based in Germany, France and Austria. K. Bremer's co-authors include Adam Noble, Stephen Dilly, Didier Cupissol, L. Goedhals, Gérard L. Bremer, A Engeset, T. M. Fliedner, Peter Schick, H.-D. Flad and H. Huber and has published in prestigious journals such as The Lancet, European Journal of Immunology and European Journal of Cancer.

In The Last Decade

K. Bremer

50 papers receiving 284 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
K. Bremer Germany	10	96	93	93	87	82	55	340
Diane Gochnour United States	7	58 0.6×	52 0.6×	140 1.5×	56 0.6×	38 0.5×	9	284
Dianne M. Howser United States	9	76 0.8×	158 1.7×	175 1.9×	64 0.7×	128 1.6×	12	491
Steven W. Papish United States	10	91 0.9×	151 1.6×	205 2.2×	42 0.5×	37 0.5×	24	438
Marijn W. M. Kruijsen Netherlands	10	45 0.5×	21 0.2×	48 0.5×	57 0.7×	53 0.6×	13	441
Harry S. Hopkins Canada	7	84 0.9×	62 0.7×	82 0.9×	35 0.4×	34 0.4×	9	288
S. Ostrow United States	13	35 0.4×	105 1.1×	235 2.5×	56 0.6×	61 0.7×	19	427
R Hoyt Australia	10	90 0.9×	114 1.2×	89 1.0×	29 0.3×	26 0.3×	13	304
Peter J.M.J. Kok Netherlands	9	91 0.9×	40 0.4×	40 0.4×	106 1.2×	69 0.8×	17	428
Papac Rj United States	6	25 0.3×	38 0.4×	139 1.5×	67 0.8×	38 0.5×	9	341
Dieter May Germany	7	41 0.4×	42 0.5×	46 0.5×	51 0.6×	59 0.7×	15	319

Countries citing papers authored by K. Bremer

Since Specialization

Citations

This map shows the geographic impact of K. Bremer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by K. Bremer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites K. Bremer more than expected).

Fields of papers citing papers by K. Bremer

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by K. Bremer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by K. Bremer. The network helps show where K. Bremer may publish in the future.

Co-authorship network of co-authors of K. Bremer

This figure shows the co-authorship network connecting the top 25 collaborators of K. Bremer. A scholar is included among the top collaborators of K. Bremer based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with K. Bremer. K. Bremer is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Bremer, K., et al.. (2009). Intraoperativer Abfall der Sevofluran- und O2-Konzentration. Der Anaesthesist. 58(12). 1226–1230. 2 indexed citations

Bremer, K., et al.. (2008). Pseudoleukozytose bei Kryoglobulinämie Typ I. DMW - Deutsche Medizinische Wochenschrift. 118(8). 260–264.

Bremer, K.. (2008). Individuelle risikoadaptierte antiemetische Stufentherapie. DMW - Deutsche Medizinische Wochenschrift. 119(16). 598–604. 1 indexed citations

Sudhoff, Holger, Dirk Theegarten, K. Bremer, et al.. (2003). Foudroyante rhinozerebrale Zygomykose. HNO. 51(11). 908–911. 5 indexed citations

Bremer, K., et al.. (1996). Comparison of the Clinical Relevance of CEA, CA 15-3 and MCA in Breast Cancer. Oncology Research and Treatment. 19(2). 170–174. 1 indexed citations

Hartung, G., U. Essers, Manfred Heim, et al.. (1995). Phase II Study of Subcutaneous Erythropoietin for Treatment of Myelodysplastic Syndromes (FAB Type I and II): A Trial of the Phase l/ll Study Group of the Association for Medical Oncology of the German Cancer Society. Oncology Research and Treatment. 18(5). 451–455. 1 indexed citations

Noble, Adam, K. Bremer, L. Goedhals, Didier Cupissol, & Stephen Dilly. (1994). A double-blind, randomised, crossover comparison of granisetron and ondansetron in 5-day fractionated chemotherapy: Assessment of efficacy, safety and patient preference. European Journal of Cancer. 30(8). 1083–1088. 50 indexed citations

Queißer, W., et al.. (1991). Phase II Study of Vinorelbine by Oral Route (in a Hard Gelatine Capsule) for Metastatic Breast Cancer Patients. Oncology Research and Treatment. 14(1). 35–39. 6 indexed citations

Bremer, K.. (1991). 5-Hydroxytryptamine (serotonin) subtype 3 antagonists, a major step in prophylaxis and control of cytostatic and radiation-induced emesis. Journal of Cancer Research and Clinical Oncology. 117(1). 85–87. 5 indexed citations

10.

Possinger, K., Helmut Wagner, P. Worst, et al.. (1991). Oral Administration of Idarubicin as First Line Cytostatic Therapy in Patients with Metastasized Breast Cancer and Favourable Prognosis. Oncology Research and Treatment. 14(1). 31–34. 11 indexed citations

11.

Wagner, Helmut, et al.. (1987). Phase II trial of 1,2,4-triglycidylurazol in patients with metastasized renal cell carcinoma.. PubMed. 71(2). 209–10. 1 indexed citations

12.

Bremer, K., et al.. (1982). Etoposide and etoposide-ifosfamide therapy for refractory testicular tumors. Cancer Treatment Reviews. 9. 79–84. 18 indexed citations

13.

Bremer, K., P. Meusers, & G Brittinger. (1980). [Chemotherapy in non-Hodgkin lymphoma].. PubMed. 21(9). 512–28. 5 indexed citations

14.

Bremer, K., A Engeset, & Frøland Ss. (1978). Circulation and emigration kinetics of blood lymphocytes in lymphoma patients.. Munich Personal RePEc Archive (Ludwig Maximilian University of Munich). 11(4). 231–7. 3 indexed citations

15.

Brittinger, G, H. Bartels, K. Bremer, et al.. (1976). [Clinical aspects of malignant non-Hodgkin's-lymphomas with reference to Kiel classification: centrocytic lymphoma, centroblastic-centrocytic lymphoma, lymphoblastic lymphoma, immunoblastic lymphoma].. Munich Personal RePEc Archive (Ludwig Maximilian University of Munich). 18. 211–23. 5 indexed citations

16.

Brittinger, G., W. Augener, K. Bremer, et al.. (1975). Der Lymphozyt bei der chronischen lymphatischen Leukämie. Annals of Hematology. 30(5). 293–308. 8 indexed citations

17.

Bremer, K., et al.. (1974). Chronic lymphoid leukemia: concentration of normal lymphocytes in the lymph.. PubMed. 21(9). 361–4. 1 indexed citations

18.

Flad, H.-D., et al.. (1973). Impaired recirculation of b lymphocytes in chronic lymphocytic leukemia. European Journal of Immunology. 3(11). 688–693. 23 indexed citations

19.

Palva, I. P., et al.. (1972). Hypercalcaemia in acute leukaemia. Annals of Hematology. 24(4). 209–225. 9 indexed citations

20.

Tm, Fliedner, et al.. (1969). [Use of tritiated thymidine and cytidine for the study of turnover and metabolism of lymphocytes in man].. PubMed. 8(5). 613–24. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact